Dispersing biofilms with engineered enzymatic bacteriophage
By Timothy K. Lu, James J. Collins. Proceedings of the National Academy of Sciences of the United States of America, 2007
871 citations recorded by the source corpus.
Subfields: Ecology, Genetics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/dbbc9502f81fa9b0faa78d65b4574289594616ba
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Ecology
In Genetics
In Molecular Biology
Citations in the corpus
- A review of microbial biofilms of produce: Future challenge to food safety (2012, background): “Lu and Collins (190) constructed engineered bacteriophages that were able to penetrate the biofilms by expressing enzymes against EPS, and successfully reduced the populations.”
- Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies (2021, methodology): “use of antibiofilm peptides like peptide 1018 [154], bacteriophage therapy [33] like anti-E.”
- Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing (2015, background): “Furthermore, despite the important role that the microbiome plays in regulating human health and disease (Grice and Segre, 2012), strategies for precisely manipulating complex microbial communities are lacking.”
- Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides (2011, positive): “Biofilm survival assays were performed as previously described 28 .”
- Phage Therapy in the Postantibiotic Era (2019, neutral): “Furthermore, Lu and Collins (146) modified E.”
- Silver Enhances Antibiotic Activity Against Gram-negative Bacteria (2013, background): “Biofilms, implicated in chronic infections of the urinary tract, lungs, skin, and other areas of the body, represent a clinical challenge due to difficulties in treating them (50).”
- Resistance of bacterial biofilms to disinfectants: a review (2011, background): “For example, a phage expressing a biofilm-degrading enzyme was engineered by one team (Lu and Collins 2007 ) and demonstrated efficacy on E.”
- Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis (2019, background): “Therefore, it is possible to engineer capsule-degrading catalytic activity into phages that lack this function (Gladstone et al., 2012; Lu and Collins, 2007).”
- Biofilm Dispersal: Mechanisms, Clinical Implications, and Potential Therapeutic Uses (2010, background): “In vitro, exogenously added dispersin B has been shown to inhibit biofilm formation, detach pre-formed biofilms, and sensitize pre-formed biofilms to killing by antimicrobial agents, bacteriophages, and host defenses in phylogenetically diverse bacteria (Kaplan et al., 2004a; Itoh et al., 2005; Lu a”
- Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections (2019, background): “In an in vitro study, Lu and Collins engineered a BP affective against an E. coli producing biofilm to express a biofilm-degrading enzyme (Lu and Collins, 2007).”
- Bacterial Biofilms: Development, Dispersal, and Therapeutic Strategies in the Dawn of the Postantibiotic Era (2013, background): “…of preformed E. coli biofilms in vitro, an effect that was more dramatic than administration of either nonengineered phage or Dispersin B alone, likely because Dispersin B-mediated degradation of EPS allowed the phage to access the deeper layers of the biofilm structure (Lu and Collins 2007).”
- A review of current and emergent biofilm control strategies (2010, background): “More recently, Lu and Collins (2007) engineered a bacteriophage to express a biofilm degrading enzyme.”